08-05-2020, 06:52 PM
|
#2615 (permalink)
|
|
.
Join Date: Aug 2012
Posts: 4,008
|
Gilead and Federal Scientists Have Neglected a Potentially Promising COVID-19 Antiviral Drug
Quote:
|
It is unclear why Gilead and federal scientists have not been pursuing GS-441524 as aggressively as remdesivir, but the answer may be found in the corporation’s patent holdings, the letter said. Gilead holds patents on both agents, but the earliest patent approval date on remdesivir is 2015, whereas the earliest on GS-441524 is 2010. As a result, the corporation’s monopoly over remdesivir may last five years longer than that for GS-441524, allowing Gilead to make substantially greater profits from the sale of remdesivir as a COVID-19 treatment.
|
|
|
|